Lisa S Kahalley1, M Douglas Ris1, Anita Mahajan2, M Fatih Okcu3, Murali Chintagumpala3, Arnold C Paulino4, William E Whitehead5, Charles G Minard6, Heather H Stancel1, Jessica Orobio1, Judy J Xue1,7, Emily A Warren8, David R Grosshans4. 1. Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston Texas. 2. Department of Radiation Oncology, Mayo Clinic, Rochester, Minneosta. 3. Department of Pediatrics, Section of Hematology Oncology, Baylor College of Medicine, Houston, Texas. 4. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Neurosurgery, Division of Pediatric Neurosurgery, Baylor College of Medicine. 6. Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas. 7. Rice University. 8. University of Houston, Department of Psychology, Houston, Texas.
Abstract
BACKGROUND: Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumor patients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only. METHODS: Patients received annual neurocognitive evaluations for up to 6 years. We examined Full Scale IQ (FSIQ), Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and Processing Speed Index (PSI) scores. General linear mixed models examined change in scores over time by treatment group, adjusting for significant covariates. RESULTS: Scores from 93 patients treated between 2012 and 2017 (22 proton CSI, 31 proton focal, and 40 surgery only) were examined. Treatment groups were similar on gender (51.6% male), age at treatment (median = 9.7 y), and length of follow-up (median = 2.9 y). The surgery only group had proportionately more gliomas (P < 0.001), and the proton CSI group had more infratentorial tumors (P = 0.001) and higher total RT dose (P = 0.004). The proton focal and surgery only groups exhibited stable neurocognitive scores over time across all indexes (all P > 0.05). In the proton CSI group, WMI, PSI, and FSIQ scores declined significantly (P = 0.036, 0.004, and 0.017, respectively), while VCI and PRI scores were stable (all P > 0.05). CONCLUSIONS: Focal PRT was associated with stable neurocognitive functioning into survivorship. Outcomes were similar whether patients received focal PRT or no radiotherapy, even in neurocognitive domains known to be particularly radiosensitive. Proton CSI emerged as a neurocognitive risk factor, consistent with photon outcomes research.
BACKGROUND: Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumorpatients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only. METHODS:Patients received annual neurocognitive evaluations for up to 6 years. We examined Full Scale IQ (FSIQ), Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and Processing Speed Index (PSI) scores. General linear mixed models examined change in scores over time by treatment group, adjusting for significant covariates. RESULTS: Scores from 93 patients treated between 2012 and 2017 (22 proton CSI, 31 proton focal, and 40 surgery only) were examined. Treatment groups were similar on gender (51.6% male), age at treatment (median = 9.7 y), and length of follow-up (median = 2.9 y). The surgery only group had proportionately more gliomas (P < 0.001), and the proton CSI group had more infratentorial tumors (P = 0.001) and higher total RT dose (P = 0.004). The proton focal and surgery only groups exhibited stable neurocognitive scores over time across all indexes (all P > 0.05). In the proton CSI group, WMI, PSI, and FSIQ scores declined significantly (P = 0.036, 0.004, and 0.017, respectively), while VCI and PRI scores were stable (all P > 0.05). CONCLUSIONS: Focal PRT was associated with stable neurocognitive functioning into survivorship. Outcomes were similar whether patients received focal PRT or no radiotherapy, even in neurocognitive domains known to be particularly radiosensitive. Proton CSI emerged as a neurocognitive risk factor, consistent with photon outcomes research.
Authors: Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Donald J Mabbott; Eric Monsalves; Brenda J Spiegler; Ute Bartels; Laura Janzen; Sharon Guger; Normand Laperriere; Nicole Andrews; Eric Bouffet Journal: Cancer Date: 2011-05-11 Impact factor: 6.860
Authors: Elizabeth M Wells; Zarir P Khademian; Karin S Walsh; Gilbert Vezina; Richard Sposto; Robert F Keating; Roger J Packer Journal: J Neurosurg Pediatr Date: 2010-04 Impact factor: 2.375
Authors: Tanya N Antonini; M Douglas Ris; David R Grosshans; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold Paulino; Amanda E Child; Jessica Orobio; Heather H Stancel; Lisa S Kahalley Journal: Radiother Oncol Date: 2017-06-24 Impact factor: 6.280
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Eric Bouffet; Murali Chintagumpala; Donald Mabbott Journal: J Clin Oncol Date: 2020-05-06 Impact factor: 44.544
Authors: Alexandra K Roth; M Douglas Ris; Jessica Orobio; Judy Xue; Anita Mahajan; Arnold C Paulino; David Grosshans; M Fatih Okcu; Murali Chintagumpala; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Amanda E Child; Emily A Warren; David R Grosshans; Arnold C Paulino; M Fatih Okcu; M Douglas Ris; Anita Mahajan; Jessica Orobio; Paul T Cirino; Charles G Minard; Andres G Viana; Johanna Bick; Steven P Woods; Murali Chintagumpala; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2021-06-11 Impact factor: 3.838
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717